{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T05:55:09Z","timestamp":1789192509023,"version":"build-2803163510"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T00:00:00Z","timestamp":1749686400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T00:00:00Z","timestamp":1749686400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"National Medical Research Council Singapore Open Fund Large Collaborative Grant","award":["NMRC\/LCG\/004\/2018"],"award-info":[{"award-number":["NMRC\/LCG\/004\/2018"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Jpn J Ophthalmol"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s10384-025-01228-w","type":"journal-article","created":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T23:16:59Z","timestamp":1749683819000},"page":"894-901","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Six-year findings of polypoidal choroidal vasculopathy in the EVEREST II study: Japanese subgroup analysis"],"prefix":"10.1007","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0362-7285","authenticated-orcid":false,"given":"Yasuo","family":"Yanagi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryusaburo","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelvin Yi Chong","family":"Teo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyu-Hyung","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nor Fariza","family":"Ngah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shih-Jen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paisan","family":"Ruamviboonsuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nagako","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won Ki","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh","family":"Rajagopalan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Obata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian Y. H.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Chee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroko","family":"Terasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuju","family":"Sekiryu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shih-Chou","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy Y. Y.","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gemmy","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeru","family":"Honda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,12]]},"reference":[{"key":"1228_CR1","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.preteyeres.2016.04.002","volume":"53","author":"CW Wong","year":"2016","unstructured":"Wong CW, Yanagi Y, Lee WK, Ogura Y, Yeo I, Wong TY, et al. Age-related macular degeneration and polypoidal choroidal vasculopathy in Asians. Prog Retin Eye Res. 2016;53:107\u201339.","journal-title":"Prog Retin Eye Res"},{"key":"1228_CR2","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.ophtha.2017.11.019","volume":"125","author":"CMG Cheung","year":"2018","unstructured":"Cheung CMG, Lai TYY, Ruamviboonsuk P, Chen S-J, Chen Y, Freund KB, et al. Polypoidal choroidal vasculopathy. Ophthalmology. 2018;125:708\u201324.","journal-title":"Ophthalmology"},{"key":"1228_CR3","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1097\/APO.0000000000000573","volume":"12","author":"P Ruamviboonsuk","year":"2023","unstructured":"Ruamviboonsuk P, Lai TYY, Chen SJ, Yanagi Y, Wong TY, Chen Y, et al. Polypoidal choroidal vasculopathy: updates on risk factors, diagnosis, and treatments. Asia-Pac J Ophthalmol. 2023;12:184\u201395.","journal-title":"Asia-Pac J Ophthalmol."},{"key":"1228_CR4","first-page":"527","volume":"6","author":"GCM Cheung","year":"2017","unstructured":"Cheung GCM, Lai TYY, Gomi F, Ruamviboonsuk P, Koh A, Lee WK. Anti-VEGF therapy for neovascular AMD and polypoidal choroidal vasculopathy. Asia-Pac J Ophthalmol. 2017;6:527\u201334.","journal-title":"Asia-Pac J Ophthalmol."},{"key":"1228_CR5","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1001\/jamaophthalmol.2017.4030","volume":"135","author":"A Koh","year":"2017","unstructured":"Koh A, Lai TYY, Takahashi K, Wong TY, Chen LJ, Ruamviboonsuk P, et al. Efficacy and safety of ranibizumab with or without verteporfin photodynamic therapy for polypoidal choroidal vasculopathy: a randomized clinical trial. JAMA Ophthalmol. 2017;135:1206\u201313.","journal-title":"JAMA Ophthalmol."},{"key":"1228_CR6","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1001\/jamaophthalmol.2018.1804","volume":"136","author":"WK Lee","year":"2018","unstructured":"Lee WK, Iida T, Ogura Y, Chen SJ, Wong TY, Mitchell P, et al. Efficacy and safety of intravitreal aflibercept for polypoidal choroidal vasculopathy in the PLANET study: a randomized clinical trial. JAMA Ophthalmol. 2018;136:786\u201393.","journal-title":"JAMA Ophthalmol."},{"key":"1228_CR7","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ajo.2019.02.027","volume":"204","author":"TY Wong","year":"2019","unstructured":"Wong TY, Ogura Y, Lee WK, Iida T, Chen SJ, Mitchell P, et al. Efficacy and safety of intravitreal aflibercept for polypoidal choroidal vasculopathy: two-year results of the aflibercept in polypoidal choroidal vasculopathy study. Am J Ophthalmol. 2019;204:80\u20139.","journal-title":"Am J Ophthalmol"},{"key":"1228_CR8","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1007\/s00417-017-3718-6","volume":"255","author":"M Morimoto","year":"2017","unstructured":"Morimoto M, Matsumoto H, Mimura K, Akiyama H. Two-year results of a treat-and-extend regimen with aflibercept for polypoidal choroidal vasculopathy. Graefes Arch Clin Exp Ophthalmol. 2017;255:1891\u20137.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1228_CR9","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1007\/s10384-018-0605-6","volume":"62","author":"M Ogasawara","year":"2018","unstructured":"Ogasawara M, Koizumi H, Yamamoto A, Itagaki K, Saito M, Maruko I, et al. Prognostic factors after aflibercept therapy for typical age-related macular degeneration and polypoidal choroidal vasculopathy. Jpn J Ophthalmol. 2018;62:584\u201391.","journal-title":"Jpn J Ophthalmol"},{"key":"1228_CR10","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s10384-017-0554-5","volume":"62","author":"Y Akagi-Kurashige","year":"2018","unstructured":"Akagi-Kurashige Y, Tsujikawa A, Yuzawa M, Ishibashi T, Nakanishi H, Nakatani E, et al. A 5-year multicenter prospective cohort study on the long-term visual prognosis and predictive factors for visual outcome in Japanese patients with age-related macular degeneration: the AMD2000 study. Jpn J Ophthalmol. 2018;62:137\u201343.","journal-title":"Jpn J Ophthalmol"},{"key":"1228_CR11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-022-26890-9","volume":"13","author":"R Mukai","year":"2023","unstructured":"Mukai R, Kataoka K, Tanaka K, Miyara Y, Maruko I, Nakayama M, et al. Three-month outcomes of faricimab loading therapy for wet age-related macular degeneration in Japan. Sci Rep. 2023;13:1\u201311.","journal-title":"Sci Rep"},{"key":"1228_CR12","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1097\/IAE.0000000000001818","volume":"38","author":"M Maruyama-Inoue","year":"2018","unstructured":"Maruyama-Inoue M, Sato S, Yamane S, Kadonosono K. Intravitreal injection of aflibercept in patients with polypoidal choroidal vasculopathy: a 3-year follow-up. Retina. 2018;38:2001\u20139.","journal-title":"Retina"},{"key":"1228_CR13","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.oret.2019.06.013","volume":"3","author":"M Hata","year":"2019","unstructured":"Hata M, Tagawa M, Oishi A, Kawashima Y, Nakata I, Akagi-Kurashige Y, et al. Efficacy of photodynamic therapy for polypoidal choroidal vasculopathy associated with and without pachychoroid phenotypes. Ophthalmol Retina. 2019;3:1016\u201325.","journal-title":"Ophthalmol Retina."},{"key":"1228_CR14","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1097\/IAE.0000000000000499","volume":"35","author":"CW Wong","year":"2015","unstructured":"Wong CW, Cheung CMG, Mathur R, Li X, Chan CM, Yeo I, et al. Three-year results of polypoidal choroidal vasculopathy treated with photodynamic therapy. Retina. 2015;35:1577\u201393.","journal-title":"Retina"},{"key":"1228_CR15","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s40123-024-00888-0","volume":"13","author":"KYC Teo","year":"2024","unstructured":"Teo KYC, Park KH, Ngah NF, Chen SJ, Ruamviboonsuk P, Mori R, et al. Six-year outcomes in subjects with polypoidal choroidal vasculopathy in the EVEREST II study. Ophthalmol Ther. 2024;13:935\u201354.","journal-title":"Ophthalmol Ther"},{"key":"1228_CR16","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1097\/APO.0000000000000445","volume":"10","author":"V Chaikitmongkol","year":"2021","unstructured":"Chaikitmongkol V, Sagong M, Lai TYY, Tan GSW, Ngah NF, Ohji M, et al. Treat-and-extend regimens for the management of neovascular age-related macular degeneration and polypoidal choroidal vasculopathy: consensus and recommendations from the Asia-Pacific Vitreo-retina Society. Asia-Pac J Ophthalmol. 2021;10:507\u201318.","journal-title":"Asia-Pac J Ophthalmol."},{"key":"1228_CR17","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1136\/bjophthalmol-2017-310448","volume":"102","author":"T Hikichi","year":"2018","unstructured":"Hikichi T. Six-year outcomes of antivascular endothelial growth factor monotherapy for polypoidal choroidal vasculopathy. Br J Ophthalmol. 2018;102:97\u2013101.","journal-title":"Br J Ophthalmol"},{"key":"1228_CR18","doi-asserted-by":"crossref","first-page":"e943","DOI":"10.1111\/aos.15015","volume":"100","author":"Y Shimizu","year":"2022","unstructured":"Shimizu Y, Miyata M, Ooto S, Miyake M, Mori Y, Tamura H, et al. Pachychoroid-phenotype effects on 5-year visual outcomes of anti-VEGF monotherapy in polypoidal choroidal vasculopathy. Acta Ophthalmol (Copenh). 2022;100:e943\u20139.","journal-title":"Acta Ophthalmol (Copenh)."},{"key":"1228_CR19","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1007\/s00417-023-05982-w","volume":"261","author":"Y Hama","year":"2023","unstructured":"Hama Y, Miyata M, Ooto S, Tamura H, Ueda-Arakawa N, Muraoka Y, et al. Seven-year outcome after 1-year fixed regimen of intravitreal aflibercept injections followed by pro re nata treatment for neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2023;261:1871\u201381.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1228_CR20","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1136\/bjophthalmol-2018-312419","volume":"103","author":"N Miyamoto","year":"2019","unstructured":"Miyamoto N, Mandai M, Oishi A, Nakai S, Honda S, Hirashima T, et al. Long-term results of photodynamic therapy or ranibizumab for polypoidal choroidal vasculopathy in LAPTOP study. Br J Ophthalmol. 2019;103:844\u20138.","journal-title":"Br J Ophthalmol"},{"key":"1228_CR21","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ajo.2012.06.027","volume":"155","author":"A Yamashita","year":"2013","unstructured":"Yamashita A, Shiraga F, Shiragami C, Shirakata Y, Fujiwara A. Two-year results of reduced-fluence photodynamic therapy for polypoidal choroidal vasculopathy. Am J Ophthalmol. 2013;155:96\u2013102.","journal-title":"Am J Ophthalmol"},{"key":"1228_CR22","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s10384-020-00734-3","volume":"64","author":"Y Komuku","year":"2020","unstructured":"Komuku Y, Iwahashi C, Gomi F. Effectiveness of polypoidal lesion-selective photodynamic therapy with intravitreal antivascular endothelial growth factor for polypoidal choroidal vasculopathy. Jpn J Ophthalmol. 2020;64:265\u201370.","journal-title":"Jpn J Ophthalmol"},{"key":"1228_CR23","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1097\/IAE.0000000000000526","volume":"35","author":"F Gomi","year":"2015","unstructured":"Gomi F, Oshima Y, Mori R, Kano M, Saito M, Yamashita A, et al. Initial versus delayed photodynamic therapy in combination with ranibizumab for treatment of polypoidal choroidal vasculopathy: the Fujisan study. Retina. 2015;35:1569\u201376.","journal-title":"Retina"}],"container-title":["Japanese Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-025-01228-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10384-025-01228-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-025-01228-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T17:05:13Z","timestamp":1762880713000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10384-025-01228-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,12]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["1228"],"URL":"https:\/\/doi.org\/10.1007\/s10384-025-01228-w","relation":{},"ISSN":["0021-5155","1613-2246"],"issn-type":[{"value":"0021-5155","type":"print"},{"value":"1613-2246","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,12]]},"assertion":[{"value":"2 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Y. Yanagi, None; R. Mori, None; K. Y. C. Teo, None; K-H. Park, None; N. F. Ngah, None; S-J. Chen, None; P. Ruamviboonsuk, None; N. Kondo, None; W. K. Lee, None; R. Rajagopalan, None; R. Obata, None; I. Y. H. Wong, None; C. Chee, None; H. Terasaki, None; T. Sekiryu, None; S-C. Chen, None; T. Y. Y. Lai, None; C. M. G. Cheung, None; S. Honda, None.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}